Shaping The Future Of Novel Therapy Development

Discover the emerging technologies revolutionising the future of novel therapy development.

Targeted therapies, personalised medicine and gene editing hold great promise for the future of novel therapy development, but challenges remain around market access, patient centricity and differentiation.

In this article, Colin Orford, Senior Vice President, Drug Development Services at ICON, shares his insights on the current trends and industry advances, including:

Leveraging synthetic biology
Widening the CGT Remit
Neurological opportunities
Regulatory matters
Planning for novel therapies

Read the Article

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By completing this form you agree ICON may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy. By clicking submit, you consent to allow Citeline to store and process the information submitted to provide you the content requested. They are subject to their Terms and Conditions.

Shaping The Future Of Novel Therapy Development

Discover the emerging technologies revolutionising the future of novel therapy development.

Read the Article

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space